Answer
Dexrazoxane hydrochloride has an average plasma elimination half-life of 2.2 ± 0.42 hours after intravenous administration to cancer patients, reported following a 12–15-minute infusion of 1000 mg/m².
Sources for this answer
- CARDIOXANE 500 mg powder for solution for infusionCNX Therapeutics Ltd (formerly Sunovion Pharmaceuticals Europe) · emc · SmPC §5.2 Pharmacokinetic properties · Version 1Document updated
Sources checked